Renaissance Capital logo

MDxHealth Priced, Nasdaq: MDXH

Belgian provider of genomic testing products for prostate cancer.

Industry: Health Care

Latest Trade: $2.00 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: -98.3%

Industry: Health Care

We are a commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. Our novel prostate cancer genomic testing solutions, SelectMDx and ConfirmMDx, provide physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications. Our unique approach combines advanced clinical modeling with genomic data to provide each patient with a personalized cancer risk profile, which provides more accurate and actionable information than standard risk factors (e.g., Prostate Specific Antigen (“PSA”), digital rectal exam (“DRE”), age) used by clinicians. Our lead products address men at risk for developing prostate cancer, but in addition, we are actively developing testing solutions to help with the management of men diagnosed with prostate cancer, with the goal to provide our clients with a menu of tools spanning the continuum of prostate cancer diagnosis and care. Our expertise in precision diagnostics and our portfolio of novel biomarkers for diagnostic, prognostic and predictive molecular assays supports our active pipeline of new testing solutions for prostate and other urologic diseases.
more less
IPO Data
IPO File Date 10/13/2021
Offer Price $12.00
Price Range $12.00 - $12.00
Offer Shares (mm) 3.8
Deal Size ($mm) $45
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/03/2021
Offer Price $12.00
Price Range $12.00 - $12.00
Offer Shares (mm) 3.8
Deal Size ($mm) $45
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Piper Sandler
Oppenheimer & Co.
more
Company Data
Headquarters Herstal, Belgium
Founded 2003
Employees at IPO 190
Website www.mdxhealth.com

MDxHealth (MDXH) Performance